ANKTIVA ® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product ImmunityBio’s 400,000 square foot GMP fill-finish facility in ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, ...

Shares of ImmunityBio Inc. IBRX are climbing with conviction during Wednesday's session. This momentum follows an ...

MoonLake gains FDA nod: Regulators agreed to include both Phase 2 and Phase 3 trial data in Sonelokimab’s proposed label, strengthening its case for approval in hidradenitis suppurativa. ImmunityBio ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

ImmunityBio Chief Executive Officer Richard Adcock acknowledges the frustration with how long it’s taken getting the Dunkirk ...

The Company reported net product revenue of approximately $44.2 million during the three months ended March 31, 2026, with net product revenue growth in every quarter since ANKTIVA’s commercial launch ...

Is IBRX a good stock to buy? We came across a bullish thesis on ImmunityBio, Inc. on Investment Ideas by Antonio’s Substack ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On ...

IBRX's Q1 outlook rides on Anktiva's surging uptake, with preliminary revenues showing triple-digit growth ahead of its ...

On this news, the price of ImmunityBio’s shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026. The case is Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261.

Cross-trial analyses comparing ANKTIVA + BCG with nadofaragene firadenovec-vncg and TAR-200 provide important context, ...